================================================================================
üèÜ TOP 5 RANKED EVIDENCE - FULL DETAILS
================================================================================

Query: What are the side effects of Pembrolizumab?
Generated: 2026-01-26 17:07:03
================================================================================


================================================================================
[1] EVIDENCE ITEM - Score: 0.950
================================================================================

Source: FDA

Title:
pembrolizumab - Drug Safety Information

Summary:
ADVERSE REACTIONS:
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling.

Severe and fatal immune-mediated adverse reactions [see Warnings and Precautions (5.1) ] .

Hypersensitivity and Administration-Related Reactions [see Warnings and Precautions (5.2) ].

The most common adverse reactions (‚â•20%) in patients treated with KEYTRUDA QLEX in combination with chemotherapy were nausea, fatigue, and musculoskeletal pain.

( 6.1 ) The safety of KEYTRUDA QLEX for


Metadata:
  ‚Ä¢ drug_name: pembrolizumab
  ‚Ä¢ purpose: N/A
  ‚Ä¢ type: drug_label

Relevance Metrics:
  ‚Ä¢ Relevance: 1.000
  ‚Ä¢ Recency: 0.500
  ‚Ä¢ Completeness: 1.000
  ‚Ä¢ Source Priority: 1.000


================================================================================
[2] EVIDENCE ITEM - Score: 0.950
================================================================================

Source: FDA

Title:
pembrolizumab - Drug Safety Information

Summary:
ADVERSE REACTIONS:
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling.

Severe and fatal immune-mediated adverse reactions [see Warnings and Precautions (5.1) ] .

Infusion-related reactions [see Warnings and Precautions (5.2) ].

Most common adverse reactions (reported in ‚â•20% of patients) were: KEYTRUDA as a single agent: fatigue, musculoskeletal pain, rash, diarrhea, pyrexia, cough, decreased appetite, pruritus, dyspnea, constipation, pain, abdominal


Metadata:
  ‚Ä¢ drug_name: pembrolizumab
  ‚Ä¢ purpose: N/A
  ‚Ä¢ type: drug_label

Relevance Metrics:
  ‚Ä¢ Relevance: 1.000
  ‚Ä¢ Recency: 0.500
  ‚Ä¢ Completeness: 1.000
  ‚Ä¢ Source Priority: 1.000

